A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron

PRODUCTS USED

Biopharma
Read Full Article

ABSTRACT

Bispecific antibodies have emerged as a promising strategy for curtailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report highlights RBT-0813 (also known as TB493-04), a synthetic, humanized, receptor-binding domain (RBD)-targeted bispecific antibody that retains picomolar affinity to the Spike (S) trimers of all major variants of concern and neutralizes both SARS-CoV-2 Delta and Omicron in vitro.

Read Full Article

PRODUCTS USED

Biopharma